Key Points
- Director Arthur Ryan sold 100 shares on May 1 at an average price of $705.24 under a pre-arranged Rule 10b5-1 plan, reducing his stake by 0.57% to 17,503 shares valued at about $12.34 million.
- Regeneron beat quarterly estimates, reporting EPS of $9.47 versus $8.91 expected and revenue of $3.61 billion versus $3.48 billion, with revenue up 19% year-over-year and a net margin around 29.7%.
- The company declared a quarterly dividend of $0.94 per share (annualized $3.76) payable June 4 with a 0.5% yield, while analysts hold a "Moderate Buy" consensus and an average target price near $826.59.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Arthur Ryan sold 100 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director directly owned 17,503 shares of the company's stock, valued at $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Regeneron Pharmaceuticals Stock Performance
Shares of REGN opened at $709.21 on Tuesday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $74.98 billion, a price-to-earnings ratio of 17.28, a PEG ratio of 1.60 and a beta of 0.30. The stock has a 50 day moving average of $756.81 and a 200 day moving average of $737.56. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts' consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals's revenue was up 19.0% on a year-over-year basis. During the same period last year, the business posted $8.22 earnings per share. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.05 earnings per share for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 9.16%.
Hedge Funds Weigh In On Regeneron Pharmaceuticals
A number of large investors have recently made changes to their positions in REGN. WPG Advisers LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 25 shares during the period. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $26,000. Salomon & Ludwin LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $27,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $29,000. Finally, Board of the Pension Protection Fund bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $31,000. 83.31% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
REGN has been the subject of a number of research analyst reports. Wall Street Zen raised Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday. Bank of America raised Regeneron Pharmaceuticals from an "underperform" rating to a "buy" rating and increased their price target for the company from $627.00 to $860.00 in a research report on Wednesday, January 7th. Wells Fargo & Company decreased their target price on Regeneron Pharmaceuticals from $825.00 to $800.00 and set an "equal weight" rating for the company in a research report on Thursday, April 30th. Weiss Ratings reissued a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, March 27th. Finally, Truist Financial decreased their target price on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a "buy" rating for the company in a research report on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $826.59.
Check Out Our Latest Analysis on REGN
About Regeneron Pharmaceuticals
(
Get Free Report)
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
